Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone970-237-5178
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees1
Next Earnings DateN/A
OptionableNot Optionable
Omni Bio Pharmaceutical (OTCMKTS:OMBP) Frequently Asked Questions
What is Omni Bio Pharmaceutical's stock symbol?
Omni Bio Pharmaceutical trades on the OTCMKTS under the ticker symbol "OMBP."
Has Omni Bio Pharmaceutical been receiving favorable news coverage?
News articles about OMBP stock have been trending somewhat positive this week, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Omni Bio Pharmaceutical earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Omni Bio Pharmaceutical.
Who are some of Omni Bio Pharmaceutical's key competitors?
Some companies that are related to Omni Bio Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO) and Spark Therapeutics (ONCE).
What other stocks do shareholders of Omni Bio Pharmaceutical own?
Who are Omni Bio Pharmaceutical's key executives?
Omni Bio Pharmaceutical's management team includes the folowing people:
- Dr. Leland Shapiro M.D., Principal Investigator for Viral & Bacterial Disorders
How do I buy shares of Omni Bio Pharmaceutical?
Shares of OMBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Omni Bio Pharmaceutical's stock price today?
One share of OMBP stock can currently be purchased for approximately $0.00.
What is Omni Bio Pharmaceutical's official website?
How can I contact Omni Bio Pharmaceutical?
Omni Bio Pharmaceutical's mailing address is 181 W BOARDWALK DRIVE SUITE 202, FORT COLLINS CO, 80525. The biopharmaceutical company can be reached via phone at 970-237-5178 or via email at [email protected]
MarketBeat Community Rating for Omni Bio Pharmaceutical (OTCMKTS OMBP)
MarketBeat's community ratings are surveys of what our community members think about Omni Bio Pharmaceutical and other stocks. Vote "Outperform" if you believe OMBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
